Home » Newsletters » BioWorld Science

BioWorld Science

May 8, 2020

View Archived Issues

Antibiotics affect oxycodone effects

Cabo as next annual shot?

FDA approves IND for Organicell Flow as treatment of SARS due to COVID-19

Positive preclinical data support IND application for CardiALLO therapy in heart failure

MGH reports progress in development of a novel gene-based COVID-19 vaccine

Pfizer presents phase II data for PF-06480605 in ulcerative colitis

RBN-2397: a first-in-class PARP-7 inhibitor with oral antitumor activity

Health Canada clears phase I trial of AC-1101 for vitiligo

Genentech reports phase Ib data for UTTR-1147A

First-in-human data for SDX-7320 in advanced refractory or late-stage solid tumors

Novel variant in the SLC6A3 gene is linked to PKDYS1 phenotype

Remdesivir receives Japanese approval for severe COVID-19

DEP irinotecan enters phase II testing after positive phase I data

Roche patents new antivirals for HBV infection

Sage Therapeutics discloses GABA-A receptor modulators

Abbisko Therapeutics identifies RORC agonists

FDA approves the initiation of phase II COVID-19 studies of PUL-042

Chinese researchers identify new TLR7 agonists

New adenosine A2B receptor antagonists patented by Leadxpro

Positive topline data presented from phase IIa study of HTD-1801 in NASH and T2DM

Ovid reports topline phase II data with OV-101 in fragile X syndrome

Evelo announces IND application to study EDP-1815 for COVID-19

Allocetra studied for COVID-19 in new phase II trial

Protagonist Therapeutics reports initial phase II data on PTG-300 in polycythemia vera

Bridge Biotherapeutics receives Korean IND clearance for BBT-176 in NSCLC

FDA clears mRNA-1273 vaccine against SARS-CoV-2 to enter phase II

PrecisionLife identifies 59 compounds based on assessment of sepsis risk genes in severe COVID-19

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 11, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 11, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
US lawmakers demand that Kennedy be held accountable
BioWorld
As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...